Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc. (SCMP), announced that it has received marketing authorization from Swissmedic, the Swiss Agency for Therapeutic Products for its Amitiza 24 microgram gel capsules for the long-term treatment of patients with chronic idiopathic constipation.
The approval is the first European regulatory approval for Sucampo and Amitiza is the first prescription medicine to be approved in Switzerland for the long-term treatment of CIC. Amitiza is already approved by the U.S. Food and Drug Administration for the long-term treatment of CIC in adults and for the treatment of irritable bowel syndrome with constipation in adult women. Amitiza is the only prescription medicine approved by the FDA for either of these indications.
Sucampo is now working on the next steps toward pricing and reimbursement to determine distribution alternatives. Sucampo's goal is to have Amitiza available for eligible patients in Switzerland.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.